Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program

被引:307
作者
Chieppa, M
Bianchi, G
Doni, A
Del Prete, A
Sironi, M
Laskarin, G
Monti, P
Piemonti, L
Biondi, A
Mantovani, A
Introna, M
Allavena, P
机构
[1] Ist Ric Farmacol Mario Negri, Dept Immunol, I-20157 Milan, Italy
[2] Ist Sci San Raffaele, Expt Surg Lab, I-20132 Milan, Italy
[3] Univ Milan, Pediat Clin, Ctr M Tettamanti, Monza, Italy
[4] Univ Milan, Inst Pathol, Milan, Italy
关键词
D O I
10.4049/jimmunol.171.9.4552
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immature monocyte-derived dendritic cells (DC) strongly express the endocytic mannose receptor (MR). Addition of a specific anti-MR mAb (clone PAM-1) for 24 111 to cultures of immature DC induced phenotypical and functional maturation of the cells, assessed as up-regulation of costimulatory molecules and CD83, and chemotactic response to CCL19. A different isotype-matched anti-MR mAb (clone 19.2) had no significant effect. Engagement of MR with mAb PAM-1 induced the production of the anti-inflammatory cytokines IL-10, IL-1R antagonist, and of the nonsignaling IL-1R type II. In contrast IL-10, TNF, and IL-12 were not produced. PAM-1-treated DC were unable to polarize Th1 effector cells and did not secrete the chemokines CXCL10 and CCL19; in turn, they produced large amounts of CCL22 and CCL17, thus favoring the amplification of Th2 circuits. T cells cocultured with PAM-1-matured DC initially proliferated but later became anergic and behaved as suppressor/regulatory cells. Natural ligands binding to MR had differential effects. MUC III (a partially purified mucin), biglycan (a purified complex proteoglycan), and mannosylated lipoarabinomannan from Mycobacterium tuberculosis affected cytokine production with high IL-10, IL-IR antagonist, IL-1R type II, and inhibition of IL-12. In contrast, mannan, dextran, and thyroglobulin had no significant effect. In conclusion, the appropriate engagement of the MR by mAb PAM-1 and selected natural ligands elicit a secretory program in mono-derived DC characterized by a distinct profile of cytokines/chemokines with the ability to dampen inflammation and to inhibit the generation of Th1-polarized immune responses.
引用
收藏
页码:4552 / 4560
页数:9
相关论文
共 60 条
[41]   Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: Evidence for a negative signal delivered through the mannose receptor [J].
Nigou, J ;
Zelle-Rieser, C ;
Gilleron, M ;
Thurnher, M ;
Puzo, G .
JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7477-7485
[42]  
OHSUMI Y, 1987, J BIOL CHEM, V262, P7955
[43]   A NEW MONOCLONAL-ANTIBODY (5D3-F7) WHICH RECOGNIZES HUMAN MONOCYTE-CHEMOTACTIC PROTEIN-1 BUT NOT RELATED CHEMOKINES - DEVELOPMENT OF A SANDWICH ELISA AND IN-SITU DETECTION OF PRODUCING CELLS [J].
PERI, G ;
MILANESE, C ;
MATTEUCCI, C ;
RUCO, L ;
ZHOU, D ;
SOZZANI, S ;
COLETTA, I ;
MANTOVANI, A .
JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 174 (1-2) :249-257
[44]  
Piemonti L, 1995, EUR CYTOKINE NETW, V6, P245
[45]   THE TYPE-II RECEPTOR AS A DECOY TARGET FOR INTERLEUKIN-1 IN POLYMORPHONUCLEAR LEUKOCYTES - CHARACTERIZATION OF INDUCTION BY DEXAMETHASONE AND LIGAND-BINDING PROPERTIES OF THE RELEASED DECOY RECEPTOR [J].
RE, F ;
MUZIO, M ;
DEROSSI, M ;
POLENTARUTTI, N ;
GIRI, JG ;
MANTOVANI, A ;
COLOTTA, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :739-743
[46]   DENDRITIC CELLS USE MACROPINOCYTOSIS AND THE MANNOSE RECEPTOR TO CONCENTRATE MACROMOLECULES IN THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II COMPARTMENT - DOWN-REGULATION BY CYTOKINES AND BACTERIAL PRODUCTS [J].
SALLUSTO, F ;
CELLA, M ;
DANIELI, C ;
LANZAVECCHIA, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (02) :389-400
[47]   Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses [J].
Sallusto, F ;
Lanzavecchia, A ;
Mackay, CR .
IMMUNOLOGY TODAY, 1998, 19 (12) :568-574
[48]   Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression [J].
Sallusto, F ;
Lanzavecchia, A .
IMMUNOLOGICAL REVIEWS, 2000, 177 :134-140
[49]  
SCHLESINGER LS, 1997, 97 ASM GEN M MIAM BE
[50]  
Shibata Y, 1997, J IMMUNOL, V159, P2462